![]() |
市場調査レポート
商品コード
1348454
静脈注射セットの世界市場:規模、シェア、動向分析(2024年~2030年):MedCoreIntravenous Set Market Size, Share & Trends Analysis | Global | 2024-2030 | MedCore | Includes: Pump Sets, Secondary Sets, and 2 more |
||||||
適宜更新あり
|
静脈注射セットの世界市場:規模、シェア、動向分析(2024年~2030年):MedCore |
出版日: 2023年09月01日
発行: iData Research Inc.
ページ情報: 英文 73 Pages
納期: 即日から翌営業日
|
2023年、世界の静脈注射セットの市場規模は堅調な伸びを示し、総評価額は60億米ドルになるとみられ、57億米ドルであった前年から5.1%の大幅増となっています。同市場は、予測期間を通じてCAGR4.1%と引き続き成長の勢いがあり、最終的には79億米ドルに達すると予測されています。世界の静脈注射セット市場の現状は、Becton Dickinson(BD)とB. Braunの2大参入企業の存在によって大きく左右されています。
進化し続ける外科手術や外傷の領域では、静脈注射セットの需要が顕著に増加しています。賑やかな病院の手術室でも、移動の多い外来環境でも、輸液療法は輸液や薬剤を正確に管理投与するためのライフラインとして極めて重要な役割を担っています。さらに、緊急の医療シナリオ、重篤な治療状況、外傷の場合には、蘇生と安定化の目的で、静脈への迅速かつ確実なアクセスが最も重要になります。このような激しく一刻を争う瞬間にこそ、一貫した血管アクセスへの不可欠なニーズが原動力となり、静脈注射セットへの要求が大幅に急増するのです。
2023年には、Becton Dickinson(BD)が世界の静脈注射セット市場の第一人者に浮上しました。BDは、長年にわたり輸液療法や関連治療市場の様々な面で確固たる地位を築いてきたことが、このようなトップクラスの地位に押し上げる上で極めて重要な役割を果たしました。BDの際立った強みは、静脈注射セットとさまざまな補完的製品をバンドルする能力にあり、この戦略は同社に大きな利益をもたらしています。この戦略により、BDは静脈注射セットを大量に、しかも競合他社が追随できないような1セットあたりの価格で提供することができるのです。
当レポートでは、世界の静脈注射セット市場について調査し、市場の概要とともに、セグメント別、地域別動向、競合情勢などを提供しています。
In 2023, the worldwide market for intravenous (IV) sets exhibited robust growth, with a total valuation of $6.0 billion, marking a substantial 5.1% increase from the previous year when it stood at $5.7 billion. Projections indicate continued growth momentum throughout the forecast period, with a compound annual growth rate (CAGR) of 4.1%, ultimately reaching an estimated value of $7.9 billion. Notably, the current landscape of the global intravenous set market is predominantly influenced by the presence of two major players, namely Becton Dickinson (BD) and B. Braun.
Our extensive medical market research efforts encompassed a comprehensive evaluation of more than 25 intravenous set companies spanning across all seven continents. Employing a rigorous methodology, we delved into various facets of the market, including market sizes, unit sales, company market shares, and generated precise forecasts. The complete report suite dedicated to the global market for intravenous sets encompasses a range of categories, including pump sets, secondary sets, gravity sets, and extension sets.
Within the ever-evolving realm of surgical procedures and trauma cases, there is a notable upswing in the demand for intravenous (IV) sets. Whether within the bustling confines of hospital operating rooms or in more mobile ambulatory settings, IV therapy assumes a pivotal role as a lifeline for the controlled administration of fluids and medications with precision. Moreover, in instances of emergent medical scenarios, critical care situations, and traumatic injuries, the immediate and dependable access to veins becomes paramount for the purpose of resuscitation and stabilization. It is within these intense and time-sensitive moments that the requirement for IV sets experiences a significant surge, driven by the indispensable need for consistent vascular access.
In the year 2023, Becton Dickinson (BD) emerged as the foremost leader in the global IV set market. BD's entrenched position in various other facets of infusion therapy and related treatment markets over the years played a pivotal role in elevating it to this top-tier status. BD's distinctive advantage lies in its ability to bundle IV sets with a range of complementary products, a strategy that bestows significant benefits upon the company. This approach occasionally empowers BD to offer IV sets in substantial quantities and at a per-set cost that smaller competitors find challenging to match.
Claiming the second position in the global IV set market for 2023 was B. Braun. The company exhibited a robust presence in the pump set market, driven by its dominant role in the realm of large-volume infusion pumps. B. Braun held a significant market share in IV sets, particularly in key Western European markets such as Germany and Italy. Beyond Western Europe, the company maintained noteworthy, albeit somewhat smaller, shares in other regions.
The remaining segment of the IV set market remained fragmented, featuring a diverse array of competitors. The relatively modest manufacturing costs associated with IV sets make this sector an attractive space for smaller players to enter. Furthermore, the majority of companies engaged in the production and distribution of infusion pumps also complement their capital products with infusion sets, thereby contributing to the diversity of offerings within the market.